Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

Neal D. Shore(Carolina Urologic Research Center), Simon Chowdhury(St Thomas' Hospital), Arnauld Villers(Université de Lille), Laurence Klotz(Sunnybrook Health Science Centre), D. Robert Siemens(Queen's University), De Phung(Astellas Pharma (Netherlands)), Steve van Os(Astellas Pharma (Netherlands)), Nahla Hasabou(Astellas Pharma (United States)), Fong Wang, Suman Bhattacharya, Axel Heidenreich(RWTH Aachen University)
The Lancet Oncology
January 13, 2016
Cited by 283

Abstract


Related Papers

No related papers found

Powered by citation graph analysis